Clinical Trial ECOGTHNR0920


A Phase III Study of Postoperative Radiation Therapy (IMRT) +/- Cetuximab for Locally-Advanced Resected Head and Neck Cancer

Principal Investigator(s)

Anthony Cmelak


  • Protocol No. ECOGTHNR0920
  • Open Date: 09/12/2012
  • Staging: Phase III
  • Age Group: Adults
  • Scope: International
  • Objective: Test whether the addition of cetuximab to radiation therapy will improve overall survival (OS) in postoperative patients with intermediate risk following surgery
  • Disease Sites: Head/Neck
  • Therapies: Molecular Targeted Agents / Immunotherapy / Biologics; Radiotherapy
  • Drugs: Cetuximab; Cetuximab (Erbitux)
  • Participating Institutions: Vanderbilt University
  • National Clinical Trial ID: NCT01311063
  • Secondary Protocol No: RTOG 0920



Learn More

You do not have JavaScript enabled. This site works better with JavaScript turned on.